Dr. Xiaojian Qin 秦晓健
Chief Physician
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of advanced and complex prostate cancer, minimally invasive nerve-sparing radical prostatectomy for early-stage disease, comprehensive management of advanced prostate cancer, benign prostatic hyperplasia, differential diagnosis of prostatitis and prostate cancer, and multidisciplinary care for urologic tumors.
Dr. Qin holds a medical doctorate and serves as Chief Physician and master’s supervisor at Fudan University Shanghai Cancer Center. Dr. Qin focuses on clinical care and basic research for urologic tumors, with expertise in prostate cancer surgery and multidisciplinary treatment. Dr. Qin has contributed to prostate cancer screening and the development of multidisciplinary teams for urologic tumors in China.
Professional roles
- Vice Chair and Secretary-General, Urology Professional Committee, China Non-Public Medical Institutions Association
- Member and Deputy Secretary-General, Integrated Prostate Tumor Committee, China Anti-Cancer Association
- Member, Prostate Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Secretary-General, Urologic Tumor Collaboration Group, Chinese Cancer Hospital
Name order: in Chinese the family name comes first (Qin Xiaojian). Papers usually list the name as Xiaojian Qin or Qin X.
Selected publications
44 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cancer, 2025 (senior author): Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization. PubMed 41039575
- Mol Med, 2022 (senior author): The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. PubMed 35836112
- BMC Med, 2022 (first author): Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. PubMed 35241087
- Curr Ther Res Clin Exp, 2021 (first author): Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis. PubMed 34917218
- World J Surg Oncol, 2015 (first author): Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study. PubMed 25943443
- World J Surg Oncol, 2015 (first author): Retrograde radical cystectomy and consequent peritoneal cavity reconstruction benefits localized male bladder cancer: results from a cohort study. PubMed 25886313
- World J Surg Oncol, 2014 (first author): Complicated variation of simple renal cyst usually means malignancy: results from a cohort study. PubMed 25315064
- Onco Targets Ther, 2013 (first author): B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma. PubMed 24265557
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion